PEB

Pacific Edge Limited

1 day chart

About PEB

Pacific Edge Limited (PEB) is a cancer diagnostics company in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Buy Australian shares starting with PEB. Invest today with a CHESS-sponsored investing platform!

Sector

Health Care

CEO

Dr Peter Meintjes

Industry

Biotechnology

Website

pacificedgedx.com

Market Capitalisation

$89M

Price-earnings ratio

-3.33

Dividend yield

NaN%

High today

$0.12

Low today

$0.11

Open price

$0.12

52-week high

$0.49

52-week low

$0.08

Announcements

PEB FAQs

Can I buy PEB shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?

Yes, the Stake platform allows you to buy PEB shares and over 8,000 stocks and ETFs across the ASX and Wall St.

How much is one share of Pacific Edge Limited?

One share of Pacific Edge Limited is valued at $0.11.

What is the ticker symbol for Pacific Edge Limited?

The ticker symbol for Pacific Edge Limited is PEB.

How do I buy PEB shares in Australia?

To buy PEB stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake AUS
Deposit directly into your Stake wallet and you're ready to invest in PEB

What is the 52-week high for Pacific Edge Limited stock?

The Pacific Edge Limited 52-week high stock price is $0.49.

What is the 52-week low for Pacific Edge Limited stock?

The Pacific Edge Limited 52-week low stock price is $0.08.

What is the market capitalisation of Pacific Edge Limited PEB?

As of 27/09/2023 Pacific Edge Limited has a market cap of $89M.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.